151 related articles for article (PubMed ID: 11067648)
1. Pharmacoeconomic analysis of antidepressants for major depressive disorder in the United Kingdom.
Freeman H; Arikian S; Lenox-Smith A
Pharmacoeconomics; 2000 Aug; 18(2):143-8. PubMed ID: 11067648
[TBL] [Abstract][Full Text] [Related]
2. A multinational pharmacoeconomic evaluation of acute major depressive disorder (MDD): a comparison of cost-effectiveness between venlafaxine, SSRIs and TCAs.
Doyle JJ; Casciano J; Arikian S; Tarride JE; Gonzalez MA; Casciano R
Value Health; 2001; 4(1):16-31. PubMed ID: 11704969
[TBL] [Abstract][Full Text] [Related]
3. Cost effectiveness of representatives of three classes of antidepressants used in major depression in the UK.
Lenox-Smith A; Conway P; Knight C
Pharmacoeconomics; 2004; 22(5):311-9. PubMed ID: 15061681
[TBL] [Abstract][Full Text] [Related]
4. A pharmacoeconomic evaluation of major depressive disorder (Italy).
Casciano J; Arikian S; Tarride JE; Doyle JJ; Casciano R
Epidemiol Psichiatr Soc; 1999; 8(3):220-31. PubMed ID: 10638040
[TBL] [Abstract][Full Text] [Related]
5. Pharmacoeconomic analysis of venlafaxine in the treatment of major depressive disorder.
Einarson TR; Addis A; Iskedjian M
Pharmacoeconomics; 1997 Aug; 12(2 Pt 2):286-96. PubMed ID: 10170453
[TBL] [Abstract][Full Text] [Related]
6. The economic impact of introducing serotonin-noradrenaline reuptake inhibitors into the Brazilian national drug formulary: cost-effectiveness and budget-impact analyses.
Machado M; Iskedjian M; Ruiz IA; Einarson TR
Pharmacoeconomics; 2007; 25(11):979-90. PubMed ID: 17960955
[TBL] [Abstract][Full Text] [Related]
7. A probabilistic cost-effectiveness analysis of escitalopram, generic citalopram and venlafaxine as a first-line treatment of major depressive disorder in the UK.
Wade AG; Toumi I; Hemels ME
Curr Med Res Opin; 2005 Apr; 21(4):631-42. PubMed ID: 15899113
[TBL] [Abstract][Full Text] [Related]
8. A model to evaluate the cost-effectiveness of oral therapies in the management of patients with major depressive disorders.
Einarson TR; Arikian S; Sweeney S; Doyle J
Clin Ther; 1995; 17(1):136-53. PubMed ID: 7758056
[TBL] [Abstract][Full Text] [Related]
9. Escitalopram: a pharmacoeconomic review of its use in depression.
Croom KF; Plosker GL
Pharmacoeconomics; 2003; 21(16):1185-209. PubMed ID: 14594439
[TBL] [Abstract][Full Text] [Related]
10. Pharmacoeconomics of antidepressants in moderate-to-severe depressive disorder in Colombia.
Machado M; Lopera MM; Diaz-Rojas J; Jaramillo LE; Einarson TR;
Rev Panam Salud Publica; 2008 Oct; 24(4):233-9. PubMed ID: 19133171
[TBL] [Abstract][Full Text] [Related]
11. Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data.
Wade AG; Fernández JL; François C; Hansen K; Danchenko N; Despiegel N
Pharmacoeconomics; 2008; 26(11):969-81. PubMed ID: 18850765
[TBL] [Abstract][Full Text] [Related]
12. C-QUALITY: cost and quality-of-life pharmacoeconomic analysis of antidepressants in major depressive disorder in Italy.
Mencacci C; Aguglia E; Biggio G; Cappellari L; Di Sciascio G; Fagiolini A; Maina G; Tortorella A; Katz P; Ripellino C
Adv Ther; 2013 Jul; 30(7):697-712. PubMed ID: 23929174
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and acceptability of pharmacological treatments for depressive disorders in primary care: systematic review and network meta-analysis.
Linde K; Kriston L; Rücker G; Jamil S; Schumann I; Meissner K; Sigterman K; Schneider A
Ann Fam Med; 2015; 13(1):69-79. PubMed ID: 25583895
[TBL] [Abstract][Full Text] [Related]
14. [Cost-effectiveness of venlafaxine for the treatment of depression and anxiety. Bibliographic review].
Baca Baldomero E; Rubio-Terrés C
Actas Esp Psiquiatr; 2006; 34(3):193-201. PubMed ID: 16736393
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness and cost-utility of tricyclic antidepressants, selective serotonin reuptake inhibitors and lofepramine: randomised controlled trial.
Kendrick T; Peveler R; Longworth L; Baldwin D; Moore M; Chatwin J; Thornett A; Goddard J; Campbell M; Smith H; Buxton M; Thompson C
Br J Psychiatry; 2006 Apr; 188():337-45. PubMed ID: 16582060
[TBL] [Abstract][Full Text] [Related]
16. Cost-effective treatment of depression with selective serotonin reuptake inhibitors.
Panzarino PJ; Nash DB
Am J Manag Care; 2001 Feb; 7(2):173-84. PubMed ID: 11216334
[TBL] [Abstract][Full Text] [Related]
17. A pharmacoeconomic study of the management of major depression: patients in a TennCare HMO.
Smith W; Sherrill A
Med Interface; 1996 Jul; 9(7):88-92. PubMed ID: 10159282
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness and cost-utility of selective serotonin reuptake inhibitors, serotonin norepinephrine reuptake inhibitors, and tricyclic antidepressants in depression with comorbid cardiovascular disease.
Pan YJ; Kuo KH; Chan HY; McCrone P
J Psychiatr Res; 2014 Jul; 54():70-8. PubMed ID: 24679672
[TBL] [Abstract][Full Text] [Related]
19. Severe depression: is there a best approach?
Sonawalla SB; Fava M
CNS Drugs; 2001; 15(10):765-76. PubMed ID: 11602003
[TBL] [Abstract][Full Text] [Related]
20. Economic considerations in the prescribing of third-generation antidepressants.
Montgomery S; Doyle JJ; Stern L; McBurney CR
Pharmacoeconomics; 2005; 23(5):477-91. PubMed ID: 15896099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
